These results revealed that disruption of the clock gene Bmal1 may be one of the underlying mechanisms contributing to diabetic cardiomyopathy, and this finding may provide a potential therapeutic target for reducing hyperglycemia cardiotoxicity. The gene discussed is BMAL1; the disease is Hyperglycemia.